These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 16236141)

  • 1. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
    Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
    Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.
    LLerena A; Dorado P; Berecz R; González AP; Peñas-LLedó EM
    Eur J Clin Pharmacol; 2004 Feb; 59(12):869-73. PubMed ID: 14726986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
    Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.
    Wang Z; Wang S; Huang M; Hu H; Yu L; Zeng S
    Chirality; 2014 Mar; 26(3):166-73. PubMed ID: 24464553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine.
    Fjordside L; Jeppesen U; Eap CB; Powell K; Baumann P; Brøsen K
    Pharmacogenetics; 1999 Feb; 9(1):55-60. PubMed ID: 10208643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers.
    Kirchheiner J; Meineke I; Müller G; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Oct; 12(7):571-80. PubMed ID: 12360109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.
    Liu ZQ; Cheng ZN; Huang SL; Chen XP; Ou-Yang DS; Jiang CH; Zhou HH
    Br J Clin Pharmacol; 2001 Jul; 52(1):96-9. PubMed ID: 11453896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
    Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of CYP450 testing in the clinical setting.
    Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
    Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes.
    Liu ZQ; Shu Y; Huang SL; Wang LS; He N; Zhou HH
    Acta Pharmacol Sin; 2001 Jan; 22(1):85-90. PubMed ID: 11730569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.
    Sagahón-Azúa J; Medellín-Garibay SE; Chávez-Castillo CE; González-Salinas CG; Milán-Segovia RDC; Romano-Moreno S
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00864. PubMed ID: 34523245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19.
    Holmgren P; Carlsson B; Zackrisson AL; Lindblom B; Dahl ML; Scordo MG; Druid H; Ahlner J
    J Anal Toxicol; 2004 Mar; 28(2):94-104. PubMed ID: 15068562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.
    LLerena A; Dorado P; Berecz R; González A; Jesús Norberto M; de la Rubia A; Cáceres M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):25-31. PubMed ID: 12450521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
    McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
    Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.